Frovatriptan in the practice of office-based neurologists/ pain therapists: Results of postmarketing surveillance study ALADIN

Advances in Therapy

Volumn 27, Issue 1, 2010, Pages 56-62

  Wallasch, Thomas Martin ^a  

^a Sankt Gertrauden Krankenhaus   (Germany)

Author keywords

Frovatriptan; Migraine Therapy; Neurologists; Pain therapists; Postmarketing surveillance study; Recurrence; Triptans

Indexed keywords

ALMOTRIPTAN; BISOPROLOL; ELETRIPTAN; FLUNARIZINE; FROVATRIPTAN; METOPROLOL; NARATRIPTAN; PETASIN; PETASITES HYBRIDUS EXTRACT; PROPRANOLOL; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERAL PRACTITIONER; HEADACHE; HEALTH CARE FACILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; NAUSEA; POSTMARKETING SURVEILLANCE; RECURRENT DISEASE; SCORING SYSTEM; TREATMENT DURATION;

ACUTE DISEASE; ADULT; CARBAZOLES; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OFFICE VISITS; PHYSICIANS, FAMILY; PRODUCT SURVEILLANCE, POSTMARKETING; RECURRENCE; SEROTONIN AGONISTS; TIME FACTORS; TRYPTAMINES;

EID: 77950690239     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0001-1     Document Type: Article

References (24)

1. Rasmussen, BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
2. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193-210.
3. Pfaffenrath,V, Fendrich K, Vennemann M, et al. Regional variations in the prevalence of migraine and tension-type headache applying the new IHS criteria: the German DMKG Headache Study. Cephalalgia. 2009;29:48-57.
4. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs. 2002;16 (suppl. 1):13-18.
5. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
6. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2009;16:968-981.
7. Evers S, May A. Acute therapy and prophylaxis of migraine - guideline of the German Migraine and Headache Society and the German Society of Neurology. Nervenheilkunde. 2008;27:933-949.
8. Lipton RB, Stewart WF, Cady R, et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache. 2000;40:783-791.
9. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache. 2002;42(suppl. 2):S84-S92.
10. Miner JR, Smith SW, Moore J, Biros M. Sumatriptan for the treatment of undifferentiated primary headaches in the ED. Am J Emerg Med. 2007;25:60-64.
11. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990;99:202-206.
12. Goadsby PJ, Akerman S, Storer RJ. Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex. Ann Neurol. 2001;50:804-807.
13. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache. 2003;43:376-388.
14. Pfaffenrath V, Spierings EH. Acute treatment of migraine attacks - frovatriptan 2.5 mg as an effective and economic alternative. Nervenheilkunde. 2004;23:545-548.
15. Diener HC, Pfaffenrath V. Efficacy and tolerability of frovatriptan in general practice - results of two PMS-studies with 16,737 migraineurs. Nervenheilkunde. 2007;26:180-185.
16. Goebel H. Erfolgreich gegen Kopfschmerzen und Migräne (Successful against headache and migraine). Heidelberg: Springer Verlag; 2004.
17. MIGARD 2.5 mg (frovatriptan) summary of product characteristics. A. Menarini Pharma. Electronic Medicines Compendium. July 2008. Available at: http://emc.medicines.org.uk/medicine/15216/spc/migard. Accessed October 23, 2008.
18. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA. 2000;284:2599-2605.
19. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20:1465-1472.
20. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006;46:914-924.
21. Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract. 2006;60:698-706.
22. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology. 2003;61:160-164.
23. Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006;46:766-772.
24. Katsarava Z, Zwarg T. Medication overuse as a risk factor for the chronification of headache. Nervenheilkunde. 2010. In press.